Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: AGN016
MIFTS: 64

Aging

Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Aging

About this section

MalaCards integrated aliases for Aging:

Name: Aging 57 76 3

External Ids:

OMIM 57 502000
Sources

Summaries for Aging

About this section
OMIM : 57 Progressive damage to mitochondrial DNA (mtDNA) during life is thought to contribute to aging processes. This notion is supported by the observation of an aging-related accumulation in human mtDNA of oxidative and alkylation derivatives of nucleotides, of small deletions and insertions, and of large deletions, although their low frequency raises questions about their functional significance (Michikawa et al., 1999). (502000)

MalaCards based summary : Aging is related to atypical werner syndrome and huntington disease. An important gene associated with Aging is BCYRN1 (Brain Cytoplasmic RNA 1
In normal aging,BC200 levels in cortical areas were reduced by >60% between the ages of 49 and 86. In contrast,BC200 RNA was significantly up-regulated in AD brains,in comparison with age-matched normal brains.
Dysfunction Pattern: Expression [differentially expressed]), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and TNFR1 Pathway. The drugs Acetylcholine and Metformin have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and heart, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Senescence (/sɪˈnɛsəns/) or biological ageing is the gradual deterioration of function characteristic of... more...

Sources

Related Diseases for Aging

About this section

Diseases related to Aging via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3509)
# Related Disease Score Top Affiliating Genes
1 atypical werner syndrome 32.4 LMNA WRN
2 huntington disease 32.0 AKT1 PPARG SNCA SOD1 TP53
3 myeloma, multiple 31.6 AKT1 JUN PARP1 TP53
4 leukemia, acute myeloid 31.5 AKT1 JUN PARP1 SNCA TP53
5 arteries, anomalies of 30.9 AKT1 PPARG SERPINE1
6 diabetes mellitus 30.2 AKT1 NAMPT PPARG SERPINE1 SOD2 WRN
7 overnutrition 30.2 AKT1 NAMPT PPARG SERPINE1
8 diabetes mellitus, noninsulin-dependent 30.1 AKT1 LMNA NAMPT PPARG SERPINE1 SIRT1
9 gastric adenocarcinoma 30.0 AKT1 HIF1A JUN TP53
10 glucose metabolism disease 30.0 AKT1 PPARG SERPINE1
11 tetraploidy 29.9 PARP1 TP53
12 ovarian cancer 29.9 AKT1 BCYRN1 HIF1A JUN PARP1 TP53
13 vascular disease 29.9 NAMPT PPARG SERPINE1 SOD1
14 esophageal cancer 29.9 AKT1 BCYRN1 HIF1A JUN TGFBR2 TP53
15 glioblastoma multiforme 29.7 AKT1 HIF1A PDGFRB PPARG TP53
16 endometrial cancer 29.5 AKT1 HIF1A JUN TGFBR2 TP53
17 nasopharyngeal carcinoma 29.5 AKT1 HIF1A JUN PARP1 TGFBR2 TP53
18 squamous cell carcinoma, head and neck 29.1 AKT1 HIF1A TP53 TP63
19 colorectal cancer 28.8 AKT1 BCYRN1 HIF1A JUN PARP1 PPARG
20 ewing sarcoma 28.8 AKT1 HIF1A JUN PARP1 PDGFRB SERPINE1
21 glioblastoma 28.8 AKT1 BCYRN1 HIF1A PDGFRB PPARG TP53
22 squamous cell carcinoma 28.4 AKT1 BCYRN1 TGFBR2 TP53 TP63
23 cervical cancer 28.3 AKT1 BCYRN1 HIF1A PARP1 TP53 TP63
24 lung cancer 27.1 AKT1 BCYRN1 HIF1A JUN PARP1 PDGFRB
25 macular degeneration, age-related, 1 12.4
26 macular degeneration, age-related, 10 12.2
27 premature aging syndrome, penttinen type 12.2
28 age-related hearing loss 12.1
29 neuropathy, hereditary, with or without age-related macular degeneration 12.1
30 macular degeneration, age-related, 2 12.1
31 macular degeneration, age-related, 5 12.1
32 macular degeneration, age-related, 13 12.1
33 macular degeneration, age-related, 7 12.1
34 macular degeneration, age-related, 8 12.1
35 macular degeneration, age-related, 4 12.1
36 macular degeneration, age-related, 9 12.1
37 macular degeneration, age-related, 11 12.1
38 macular degeneration, age-related, 6 12.1
39 macular degeneration, age-related, 12 12.1
40 macular degeneration, age-related, 14 12.1
41 macular degeneration, age-related, 15 12.1
42 age-related hearing impairment 1 12.0
43 age-related hearing impairment 2 12.0
44 cataract, age-related nuclear 12.0
45 short stature and advanced bone age, with or without early-onset osteoarthritis and/or osteochondritis dissecans 11.9
46 menarche, age at, quantitative trait locus 1 11.9
47 menopause, natural, age at, quantitative trait locus 1 11.8
48 premature aging syndrome, okamoto type 11.8
49 menopause, natural, age at, quantitative trait locus 2 11.8
50 menopause, natural, age at, quantitative trait locus 4 11.8

Graphical network of the top 20 diseases related to Aging:



Diseases related to Aging
Sources

Symptoms & Phenotypes for Aging

About this section

Clinical features from OMIM:

502000

GenomeRNAi Phenotypes related to Aging according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00107-A-1 10.56 TGFBR2
2 Decreased viability GR00221-A-1 10.56 TGFBR2 AKT1 PDGFRB PPARG
3 Decreased viability GR00221-A-2 10.56 SOD1 AKT1 JUN PPARG
4 Decreased viability GR00221-A-3 10.56 SOD1 TGFBR2 AKT1 JUN PDGFRB PPARG
5 Decreased viability GR00221-A-4 10.56 SOD1 TGFBR2 AKT1 PDGFRB PPARG
6 Decreased viability GR00342-S-1 10.56 PDGFRB
7 Decreased viability GR00402-S-2 10.56 TGFBR2 AKT1 JUN PDGFRB PPARG SOD1
8 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 AKT1 HIF1A JUN SIRT1 SNCA SOD1
9 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 AKT1 HIF1A JUN SIRT1 SNCA SOD1
10 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.56 HIF1A JUN PARP1 SIRT1 SOD1 TP53

MGI Mouse Phenotypes related to Aging:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.55 SNCA SOD1 SOD2 TGFBR2 TP53 TP63
2 growth/size/body region MP:0005378 10.54 AKT1 HIF1A JUN KL LMNA NAMPT
3 cellular MP:0005384 10.52 AKT1 HIF1A JUN KL LMNA PARP1
4 homeostasis/metabolism MP:0005376 10.51 AKT1 HIF1A JUN KL LMNA NAMPT
5 behavior/neurological MP:0005386 10.5 AKT1 HIF1A JUN KL LMNA PARP1
6 immune system MP:0005387 10.5 AKT1 HIF1A JUN KL LMNA NAMPT
7 endocrine/exocrine gland MP:0005379 10.47 AKT1 HIF1A JUN KL LMNA NAMPT
8 hematopoietic system MP:0005397 10.47 AKT1 HIF1A JUN KL LMNA NAMPT
9 integument MP:0010771 10.47 AKT1 HIF1A JUN KL LMNA NAMPT
10 mortality/aging MP:0010768 10.45 SOD1 SOD2 TGFBR2 TP53 TP63 WRN
11 adipose tissue MP:0005375 10.37 AKT1 KL LMNA PDGFRB PPARG SERPINE1
12 embryo MP:0005380 10.34 PDGFRB PPARG SIRT1 TGFBR2 TP53 TP63
13 nervous system MP:0003631 10.31 KL LMNA NAMPT PARP1 PDGFRB PPARG
14 digestive/alimentary MP:0005381 10.3 HIF1A KL LMNA PDGFRB SIRT1 SNCA
15 liver/biliary system MP:0005370 10.29 TGFBR2 TP53 PPARG SERPINE1 SIRT1 SOD1
16 craniofacial MP:0005382 10.26 HIF1A KL LMNA PDGFRB SIRT1 TGFBR2
17 muscle MP:0005369 10.22 AKT1 HIF1A KL LMNA PDGFRB PPARG
18 neoplasm MP:0002006 10.2 HIF1A PPARG SERPINE1 SIRT1 SOD1 SOD2
19 hearing/vestibular/ear MP:0005377 10.18 KL LMNA PARP1 PPARG SIRT1 SOD1
20 limbs/digits/tail MP:0005371 10.13 LMNA PDGFRB SIRT1 TP53 TP63 WRN
21 normal MP:0002873 10.11 JUN LMNA PDGFRB PPARG SIRT1 SNCA
22 renal/urinary system MP:0005367 10.1 HIF1A KL LMNA PARP1 PDGFRB PPARG
23 reproductive system MP:0005389 10.07 LMNA PARP1 PDGFRB PPARG SIRT1 SNCA
24 no phenotypic analysis MP:0003012 9.95 JUN PARP1 PPARG SIRT1 SNCA TP53
25 respiratory system MP:0005388 9.85 AKT1 HIF1A JUN KL LMNA SERPINE1
26 skeleton MP:0005390 9.8 AKT1 HIF1A JUN KL LMNA PDGFRB
27 vision/eye MP:0005391 9.47 HIF1A JUN KL LMNA PARP1 PDGFRB
Sources

Drugs & Therapeutics for Aging

About this section

Drugs for Aging (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 876)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
2
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 657-24-9 14219 4091
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
4
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
5
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 113775-47-6 68602 5311068
6
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
7
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
8
Clopidogrel Approved Phase 4,Phase 3 120202-66-6, 113665-84-2 60606
9
Pantoprazole Approved Phase 4 102625-70-7 4679
10
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
11
Digoxin Approved Phase 4 20830-75-5 30322 2724385
12
Cobicistat Approved Phase 4 1004316-88-4
13
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
14
Rilpivirine Approved Phase 4 500287-72-9
15
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
16
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 71-58-9
17
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
18
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010
19
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
20
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 315-37-7 9416
21
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5949-44-0
22
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120014-06-4 3152
23
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
24
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
25
Ethanol Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 64-17-5 702
26
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
27
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 137-58-6 3676
28
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 124-94-7 31307
29
Celecoxib Approved, Investigational Phase 4,Phase 3 169590-42-5 2662
30
Ibuprofen Approved Phase 4,Phase 3,Phase 1,Not Applicable 15687-27-1 3672
31
Armodafinil Approved, Investigational Phase 4,Phase 2 112111-43-0
32
Modafinil Approved, Investigational Phase 4,Phase 2 68693-11-8 4236
33
Naproxen Approved, Vet_approved Phase 4,Phase 2,Phase 3 22204-53-1 1302 156391
34
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
35 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 979-32-8
36
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 28014-46-2
37
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 23994
38
Mannitol Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 69-65-8 453 6251
39
Loperamide Approved Phase 4,Early Phase 1,Not Applicable 53179-11-6 3955
40
Pectin Approved, Investigational, Vet_approved Phase 4,Not Applicable 9000-69-5 441476
41
Citalopram Approved Phase 4,Phase 3,Not Applicable 59729-33-8 2771
42
Pravastatin Approved Phase 4,Phase 3 81093-37-0 54687
43
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
44
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
45
Abacavir Approved, Investigational Phase 4,Phase 3 136470-78-5 65140 441300
46 Dolutegravir Approved Phase 4,Phase 3 1051375-16-6 54726191
47
Lamivudine Approved, Investigational Phase 4,Phase 3 134678-17-4 60825
48
Desflurane Approved Phase 4 57041-67-5 42113
49
Kinetin Approved Phase 4 525-79-1 3830
50
Polidocanol Approved Phase 4 9002-92-0

Interventional clinical trials:

(show top 50) (show all 3292)
# Name Status NCT ID Phase Drugs
1 Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Unknown status NCT01583478 Phase 4
2 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
3 Metformin Induces a Dietary Restriction-like State in Human Unknown status NCT02745886 Phase 4 metformin 0.85 twice daily for 6 months
4 Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study Unknown status NCT02326038 Phase 4 Methylphenidate
5 Rosuvastatin Effect on Telomere-telomerase System in ACS Unknown status NCT02299245 Phase 4 rosuvastatin
6 Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty Unknown status NCT01934049 Phase 4 Total Intravenous Anesthesia and Peripheral nerve blocks
7 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
8 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo
9 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
10 The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders Unknown status NCT02357472 Phase 4 dehydroepiandrosterone
11 The Impact of Hyaluronic Acid Injections on Osteoarthritic Knee Mechanics Unknown status NCT00778076 Phase 4
12 The Effects of Blood Pressure Reduction on Cerebral Perfusion and Cognition in the Elderly Population Unknown status NCT00966199 Phase 4 anti-hypertensive medication
13 Herbal Alternatives for Menopause Symptoms (HALT Study) Unknown status NCT00169299 Phase 4 Black cohosh;Multibotanical preparation;Multibotanical preparation + dietary soy counseling;Conjugated equine estrogen +/- medroxyprogesterone acetate
14 A Dose Finding Study for Pain Relief of a Broken Hip Unknown status NCT00926666 Phase 4 Levobupivacaine
15 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
16 Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause Unknown status NCT01116310 Phase 4 Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L);Placebo
17 CALM-AD Unknown status NCT00142324 Phase 4 Donepezil
18 Retinol on Human Skin Aging in East Asian Descent Completed NCT02906566 Phase 4 Retinol;Placebo
19 Volume Restoration of the Aging Midface With Sculptra Aesthetic Completed NCT01307865 Phase 4 injectable poly-L-lactic acid
20 Changing in Skin Physiology After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces Completed NCT02312154 Phase 4
21 Pectin, Aging and Intestinal Barrier Function Completed NCT02376270 Phase 4
22 Brain Imaging and Mental Disorders of Aging Intervention Completed NCT00267163 Phase 4 donepezil;Placebo
23 PPV: Pneumococcal Polysaccharide Vaccine in Older Adults Completed NCT00239694 Phase 4
24 Canadian Aesthetic Experience With Sculptra Therapy Completed NCT00447551 Phase 4 Poly-L-Lactic Acid
25 Metformin in Longevity Study (MILES). Completed NCT02432287 Phase 4 Metformin;Placebo
26 Aging Brain Changes, Executive Dysfunction and Depression Completed NCT00918684 Phase 4 Escitalopram
27 Memory and Mental Health in Aging Completed NCT02988908 Phase 4 Donepezil;Placebos
28 Testosterone Effects on Bone and Frailty Completed NCT00182871 Phase 4 testosterone
29 The Effect of Luteinizing Hormone (LH) Supplementation Following Gonadotropin-releasing Hormone (GnRH) Antagonist Administration in Advanced Reproductive Ageing Women Undergoing IVF and Embryo Transfer (IVF/ET) Completed NCT01016210 Phase 4 Leuveris;Leuveris
30 Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules Completed NCT02765763 Phase 4 2-Minute Reveal Masque;24/7 Barrier Repair Cream;8-in-1 BioSerum;Null Formula 2-Minute Reveal Masque;Null Formula 24/7 Barrier Repair Cream;Null Formula 8-in-1 BioSerum
31 Effect of a Transcutaneous Electrical Nerve Stimulation (TENS) Device on Overall Facial Appearance Completed NCT01740440 Phase 4
32 Comparative Study of the Effect of Dysport and Botox Completed NCT00434863 Phase 4 botulinum toxin type A
33 Poly-L-lactic Acid for Skin Quality Completed NCT02003833 Phase 4
34 Evaluation of Radiesse® Dermal Filler for Hand Rejuvenation Completed NCT01004107 Phase 4
35 Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women Completed NCT01598272 Phase 4
36 Comparison of Outcome Parameters in Laser Rhytide Treatment Completed NCT00994474 Phase 4
37 Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines Completed NCT00856414 Phase 4
38 Comparative Study of Reconstituted JUVÉDERM® Ultra vs COSMODERM® 1 for Lip and Cheek Lines, Folds or Wrinkles Completed NCT01212809 Phase 4
39 Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
40 Metformin and Longevity Genes in Prediabetes Completed NCT01765946 Phase 4 Metformin;placebo
41 Do HMG CoA Reductase Inhibitors Affect Abeta Levels? Completed NCT00303277 Phase 4 simvastatin;pravastatin
42 Optimizing Body Composition for Function in Older Adults Completed NCT00315146 Phase 4 Pioglitazone;Placebo
43 Effect of Revival Soy on Weight Loss and Skin, Hair, and Nails in Premenopausal Women Completed NCT00352157 Phase 4
44 Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study Completed NCT01529788 Phase 4 Right lateral orbital injection of Botox Cosmetic or Dysport;Left lateral orbital injection of Botox Cosmetic or Dysport
45 Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men Completed NCT00957801 Phase 4 Testosterone injection;Testosterone gel;Medrol
46 Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands Completed NCT01910831 Phase 4 DerMend Moisturizing Bruise Formula
47 Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients Completed NCT00599807 Phase 4
48 Effects of DHEA/Exercise on Bone, Muscle and Balance Completed NCT00664053 Phase 4
49 Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma Fatty Acids Completed NCT02410161 Phase 4
50 Donepezil in Preventing Delirium in Hospitalized Elderly Completed NCT00182884 Phase 4 Donepezil

Search NIH Clinical Center for Aging

Sources

Genetic Tests for Aging

About this section
Sources

Anatomical Context for Aging

About this section

MalaCards organs/tissues related to Aging:

41
Brain, Bone, Heart, Skin, Breast, Endothelial, Prostate
Sources

Publications for Aging

About this section

Articles related to Aging:

(show top 50) (show all 18904)
# Title Authors Year
1
Chronic pain and geriatric syndromes in community-dwelling patients aged a8Y65 years. ( 29950889 )
2018
2
The influence of age on valve disease in patients with varicose veins analysed by transmission electron microscopy and stereology. ( 29808768 )
2018
3
Testosterone- and Cortisol-secreting Oncocytic Adrenocortical Adenoma in the Pediatric Age-group. ( 29426273 )
2018
4
Perioperative neonatal brain injury is associated with worse school-age neurodevelopment in children with critical congenital heart disease. ( 29572821 )
2018
5
MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen. ( 29370035 )
2018
6
The Enzymatic Core of the Parkinson's Disease-Associated Protein LRRK2 Impairs Mitochondrial Biogenesis in Aging Yeast. ( 29977190 )
2018
7
Esophageal cancer male to female incidence ratios in Africa: A systematic review and meta-analysis of geographic, time and age trends. ( 29414631 )
2018
8
Risk Factors of Vulvovaginal Candidiasis among Women of Reproductive Age in Xi'an: A Cross-Sectional Study. ( 29977925 )
2018
9
Age and gender may be the key points in hyperglycemic patients with Helicobacter pylori infection combined colorectal adenoma-author's reply. ( 29644785 )
2018
10
Iron deficiency and iron deficiency anemia in children aged 6-36 months: Is there room for improvement of screening, prophylaxis and treatment? ( 29258914 )
2018
11
Functional Change in the Caudal Pontine Reticular Nucleus Induced by Age-Related Hearing Loss. ( 29853848 )
2018
12
Socio-economic patterning in early mortality of patients aged 0-49 years diagnosed with primary bone cancer in Great Britain, 1985-2008. ( 29414632 )
2018
13
Functionality in Middle-Aged and Older Overweight and Obese Individuals with Knee Osteoarthritis. ( 29973574 )
2018
14
Response by Elming et al to Letter Regarding Article, "Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure". ( 29760232 )
2018
15
Incidence and epidemiology of intussusception among children under 2a8^years of age in Chenzhou and Kaifeng, China, 2009-2013. ( 29439864 )
2018
16
Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes. ( 29361745 )
2018
17
A parthenogenetic quasi-program causes teratoma-like tumors during aging in wild-type <i>C. elegans</i>. ( 29928508 )
2018
18
Gastroesophageal Reflux Frequency, Severity, Age of Onset, Family History and Acid Suppressive Therapy Predict Barrett Esophagus in a Large Population. ( 29356784 )
2018
19
Physical and psychosocial factors in the prevention of chronic pain in older age. ( 29949780 )
2018
20
Ovarian Yolk Sac Tumors; Does Age Matter? ( 29194189 )
2018
21
Aging effects on symbolic number comparison: No deceleration of numerical information retrieval but more conservative decision-making. ( 29975082 )
2018
22
Quantitative analysis of the safety and efficacy of microvascular decompression for patients with trigeminal neuralgia above and below 65a8^years of age. ( 29954647 )
2018
23
Chronic pulmonary disease is associated with pain spreading and restless legs syndrome in middle-aged women-a population-based study. ( 29869108 )
2018
24
Interaction of HLA-DRB1* alleles and CTLA4 (+49 AG) gene polymorphism in Autoimmune Thyroid Disease. ( 29174716 )
2018
25
Burden of Depression among Working-Age Adults with Rheumatoid Arthritis. ( 29971163 )
2018
26
Glucose metabolism during the acute prostate cancer treatment trajectory: The influence of age and obesity. ( 27998647 )
2018
27
Prevalence of sleep problems and sleep-related characteristics in preschool- and school-aged children with cerebral palsy. ( 29966807 )
2018
28
Solitary facet joint osteochondroma of the upper thoracic spine: An unusual cause of cord compression in the pediatric age group. ( 29547195 )
2018
29
Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small-for-gestational-age child: a systematic review and meta-analysis. ( 29753309 )
2018
30
Prevalence and characteristics of overweight and obesity among Chinese youth aged 12-18 years: a multistage nationwide survey. ( 29180035 )
2018
31
The trends and prevalence of obesity and morbid obesity among Australian school-aged children, 1985-2014. ( 29667237 )
2018
32
Vitamin B12 deficiency and impaired expression of amnionless during aging. ( 29159972 )
2018
33
Spontaneous malignant myoid thymoma in an aged female Fischer 344 rat. ( 29750002 )
2018
34
Gradual Phenotype Development in Huntington Disease Transgenic Minipig Model at 24 Months of Age. ( 29870995 )
2018
35
Clinicopathological Characteristics of Traumatic Head Injury in Juvenile, Middle-Aged and Elderly Individuals. ( 29773781 )
2018
36
Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. ( 29385725 )
2018
37
Effects of carvacrol on human fibroblast (WS-1) and gastric adenocarcinoma (AGS) cells in vitro and on Wistar rats in vivo. ( 29442269 )
2018
38
Prominent exostosis projecting from the occipital squama more substantial and prevalent in young adult than older age groups. ( 29463874 )
2018
39
The effectiveness of sphero-cylindrical correction at a short distance in presbyopic age patients with the first detected astigmatism. ( 29783210 )
2018
40
Exposure to traffic-related air pollution and acute bronchitis in children: season and age as modifiers. ( 29440305 )
2018
41
Relative age effects in Swiss talent development - a nationwide analysis of all sports. ( 29392997 )
2018
42
Cognitive control under stressful conditions in transitional age youth with bipolar disorder: Diagnostic and sleep-related differences in fronto-limbic activation patterns. ( 29441653 )
2018
43
Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45. ( 29317118 )
2018
44
Rotavirus infection among hospitalized children under five years of age with acute watery diarrhea in Sri Lanka. ( 29945833 )
2018
45
Histologic chorioamnionitis in preterm infants: correlation with brain magnetic resonance imaging at term equivalent age. ( 29448926 )
2018
46
Hormonal contraceptive use and smoking as risk factors for high-grade cervical intraepithelial neoplasia in unvaccinated women aged 30-44 years: A case-control study in New South Wales, Australia. ( 29980028 )
2018
47
Ageing with a learning disability: Care and support in the context of austerity. ( 29580648 )
2018
48
Does the Movement Assessment Battery for Children-2 at 3 years of age predict developmental coordination disorder at 4.5 years of age in children born very preterm? ( 29653831 )
2018
49
Pulling back the curtain: Issues in conducting an intervention study with transition-aged youth with autism spectrum disorder and their families. ( 29439586 )
2018
50
Long-term evolution of age-related distance esotropia. ( 29551605 )
2018
Sources

Variations for Aging

About this section
Sources

Expression for Aging

About this section
Search GEO for disease gene expression data for Aging.
Sources

Pathways for Aging

About this section

Pathways related to Aging according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Cellular Senescence (REACTOME) 66
Show member pathways
 13.14 HIF1A JUN SIRT1 SOD1 SOD2 TP53
2
TNFR1 Pathway 64
Show member pathways
 12.88 AKT1 JUN LMNA PARP1 TP53
3
Endometrial cancer 37
Show member pathways
 12.83 AKT1 JUN PDGFRB PPARG TGFBR2 TP53
4
MAPK signaling pathway 1 37
12.76 AKT1 JUN PDGFRB TGFBR2 TP53
5
Apoptosis Modulation and Signaling 1
Show member pathways
 12.76 AKT1 JUN LMNA PARP1 TP53 TP63
6
Pathways in cancer 37
12.7 AKT1 HIF1A JUN PDGFRB PPARG TGFBR2
7
4-1BB Pathway 64
Show member pathways
 12.65 AKT1 JUN PDGFRB SIRT1 TP53
8
Glucose / Energy Metabolism 4
12.52 AKT1 NAMPT PPARG SIRT1 SOD2
9
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.43 AKT1 PPARG SIRT1 TP53
10
Phospholipase D signaling pathway 37
Show member pathways
 12.4 AKT1 HIF1A JUN PDGFRB
11
Apoptosis Pathway 72
Show member pathways
 12.4 AKT1 JUN PDGFRB TGFBR2 TP53
12
HTLV-I infection 37
12.37 AKT1 JUN PDGFRB TGFBR2 TP53
13
Folate Metabolism 1
Show member pathways
 12.32 SERPINE1 SOD1 SOD2 TP53
14
p53 Signaling 64
Show member pathways
 12.25 AKT1 HIF1A SIRT1 TP53
15
BMAL1-CLOCK,NPAS2 activates circadian gene expression 66
Show member pathways
 12.22 HIF1A NAMPT SERPINE1 SIRT1
16
Apoptosis and survival Caspase cascade 22
Show member pathways
 12.2 AKT1 JUN LMNA PARP1
17
AKT Signaling Pathway 67
12.15 AKT1 LMNA PDGFRB TP53
18
mTOR Pathway 72
Show member pathways
 12.1 AKT1 JUN PPARG TGFBR2 TP53
19
Cellular senescence (KEGG) 37
12.08 AKT1 SERPINE1 SIRT1 TGFBR2 TP53
20
FoxO signaling pathway 37
Show member pathways
 12.07 AKT1 SIRT1 SOD2 TGFBR2
22
TGF-beta Signaling Pathway (WikiPathways) 1
12.04 AKT1 JUN TGFBR2 TP53
23
Integrated Breast Cancer Pathway 1
12.04 AKT1 JUN SIRT1 TGFBR2 TP53
24
Direct p53 effectors 1
12.03 JUN SERPINE1 TP53 TP63
25
Osteoclast differentiation 37
12.01 AKT1 JUN PPARG TGFBR2
26
DNA Damage Response (only ATM dependent) 1
11.95 AKT1 JUN SOD2 TP53
27
UVA-Induced MAPK Signaling 64
Show member pathways
 11.92 AKT1 JUN TP53
28
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 11.89 AKT1 HIF1A JUN PPARG SERPINE1 TP53
29
Androgen receptor signaling pathway 1
11.85 AKT1 JUN SIRT1
30
AGE-RAGE signaling pathway in diabetic complications 37
11.85 AKT1 JUN SERPINE1 TGFBR2
31
Adipogenesis 1
11.84 HIF1A LMNA NAMPT PPARG SERPINE1
32
TGF-beta Signaling Pathways 65
11.83 AKT1 JUN PPARG TGFBR2
33
TP53 Regulates Metabolic Genes 66
11.82 AKT1 TP53 TP63
34
VEGF Pathway (Tocris) 72
Show member pathways
 11.8 AKT1 JUN PDGFRB
35
Glucocorticoid receptor regulatory network 1
11.79 AKT1 JUN TP53
36
Regulation of nuclear SMAD2/3 signaling 1
11.77 AKT1 JUN SERPINE1
37
Sterol Regulatory Element-Binding Proteins (SREBP) signalling 1
11.74 AKT1 PPARG SIRT1
38
Association Between Physico-Chemical Features and Toxicity Associated Pathways 1
11.7 AKT1 JUN SOD1
39
Regulation of Telomerase 1
11.68 AKT1 JUN WRN
40
Longevity regulating pathway 37
Show member pathways
 11.68 AKT1 KL PPARG SIRT1 SOD1 SOD2
41
Mitophagy - animal 37
11.67 HIF1A JUN TP53
42
AGE/RAGE pathway 1
11.66 AKT1 HIF1A JUN SOD1
43
Central carbon metabolism in cancer 37
11.64 AKT1 HIF1A PDGFRB TP53
44
TGF-beta Receptor Signaling (WikiPathways) 1
11.62 JUN SERPINE1 TGFBR2
45
HIF-1-alpha transcription factor network 1
11.62 AKT1 HIF1A JUN SERPINE1
46
Regulation of retinoblastoma protein 1
11.6 JUN PPARG SIRT1
47
HIF1Alpha Pathway 64
11.57 HIF1A JUN TP53
48
PDGFR-beta signaling pathway 1
11.57 AKT1 HIF1A PDGFRB
49
Proteolysis Putative SUMO-1 pathway 22
Show member pathways
 11.57 AKT1 JUN TP53
50
FoxO family signaling 1
11.5 AKT1 SIRT1 SOD2
Sources

GO Terms for Aging

About this section

Cellular components related to Aging according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.86 AKT1 PARP1 SIRT1 SNCA SOD1 SOD2
2 nucleoplasm GO:0005654 9.7 AKT1 HIF1A JUN LMNA PARP1 PPARG
3 nuclear chromatin GO:0000790 9.62 JUN SIRT1 TP53 TP63
4 transcription factor complex GO:0005667 9.46 HIF1A JUN PARP1 TP63
5 protein-containing complex GO:0032991 9.1 AKT1 HIF1A PARP1 PPARG SOD1 TP53
6 nucleus GO:0005634 10.21 AKT1 HIF1A JUN LMNA NAMPT PARP1

Biological processes related to Aging according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of angiogenesis GO:0045766 9.96 HIF1A SERPINE1 SIRT1 TGFBR2
2 regulation of signal transduction by p53 class mediator GO:1901796 9.95 AKT1 TP53 TP63 WRN
3 response to oxidative stress GO:0006979 9.94 AKT1 SIRT1 SOD1 WRN
4 rhythmic process GO:0048511 9.93 NAMPT PPARG SIRT1 TP53
5 negative regulation of apoptotic process GO:0043066 9.91 AKT1 HIF1A JUN PDGFRB SIRT1 SNCA
6 cellular response to insulin stimulus GO:0032869 9.9 AKT1 PARP1 PPARG
7 insulin receptor signaling pathway GO:0008286 9.89 AKT1 KL NAMPT
8 protein homotetramerization GO:0051289 9.89 SOD2 TP53 TP63
9 regulation of blood pressure GO:0008217 9.88 PPARG SOD1 SOD2
10 transforming growth factor beta receptor signaling pathway GO:0007179 9.88 JUN PARP1 SIRT1 TGFBR2
11 cellular response to oxidative stress GO:0034599 9.88 PARP1 SNCA SOD1 SOD2
12 negative regulation of neuron apoptotic process GO:0043524 9.88 HIF1A JUN SNCA SOD1 SOD2
13 response to mechanical stimulus GO:0009612 9.87 JUN PPARG TGFBR2
14 response to estrogen GO:0043627 9.87 PDGFRB PPARG TGFBR2
15 negative regulation of neuron death GO:1901215 9.86 AKT1 SIRT1 SNCA
16 cellular response to UV GO:0034644 9.86 PARP1 TP53 TP63
17 circadian rhythm GO:0007623 9.86 JUN NAMPT SERPINE1 SIRT1
18 outflow tract morphogenesis GO:0003151 9.85 HIF1A JUN TGFBR2
19 positive regulation of blood vessel endothelial cell migration GO:0043536 9.85 AKT1 HIF1A SIRT1
20 response to organic cyclic compound GO:0014070 9.85 JUN NAMPT PDGFRB PPARG TGFBR2
21 positive regulation of endothelial cell proliferation GO:0001938 9.83 AKT1 HIF1A JUN SIRT1
22 cellular response to hypoxia GO:0071456 9.83 AKT1 HIF1A LMNA SIRT1 TP53
23 positive regulation of epithelial cell migration GO:0010634 9.82 HIF1A JUN TGFBR2
24 cellular response to cadmium ion GO:0071276 9.82 AKT1 JUN SOD1
25 response to hydrogen peroxide GO:0042542 9.8 JUN PDGFRB SIRT1 SOD1
26 response to organic substance GO:0010033 9.8 AKT1 JUN PPARG SOD1 TGFBR2
27 response to gamma radiation GO:0010332 9.79 PARP1 TP53 TP63
28 positive regulation of reactive oxygen species metabolic process GO:2000379 9.79 PDGFRB TGFBR2 TP53
29 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.78 SIRT1 TP53 TP63
30 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.77 HIF1A JUN TP53
31 positive regulation of apoptotic process GO:0043065 9.76 AKT1 JUN PDGFRB PPARG SIRT1 SNCA
32 removal of superoxide radicals GO:0019430 9.73 SOD1 SOD2
33 white fat cell differentiation GO:0050872 9.73 PPARG SIRT1
34 replicative senescence GO:0090399 9.72 SERPINE1 TP53
35 positive regulation of smooth muscle cell proliferation GO:0048661 9.72 AKT1 JUN NAMPT PDGFRB TGFBR2
36 mitotic G1 DNA damage checkpoint GO:0031571 9.71 TP53 TP63
37 negative regulation of telomerase activity GO:0051974 9.71 PPARG TP53
38 response to fluid shear stress GO:0034405 9.7 AKT1 PDGFRB
39 peripheral nervous system myelin maintenance GO:0032287 9.7 AKT1 SOD1
40 retina vasculature development in camera-type eye GO:0061298 9.69 HIF1A PDGFRB
41 oxygen homeostasis GO:0032364 9.69 HIF1A SOD2
42 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.69 AKT1 SIRT1 SOD2
43 response to superoxide GO:0000303 9.68 SOD1 SOD2
44 replicative cell aging GO:0001302 9.67 TP63 WRN
45 negative regulation of helicase activity GO:0051097 9.62 SIRT1 TP53
46 cell aging GO:0007569 9.35 SIRT1 SOD1 TP53 TP63 WRN
47 aging GO:0007568 9.32 AKT1 JUN KL PDGFRB SNCA SOD1
48 transcription by RNA polymerase II GO:0006366 10.15 HIF1A JUN PARP1 SIRT1 TP53 TP63
49 positive regulation of transcription, DNA-templated GO:0045893 10.14 AKT1 HIF1A JUN PPARG TP53 TP63
50 negative regulation of transcription by RNA polymerase II GO:0000122 10.14 JUN PARP1 PPARG SIRT1 SNCA TP53

Molecular functions related to Aging according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.88 AKT1 HIF1A PARP1 PDGFRB TP53
2 chromatin binding GO:0003682 9.85 JUN PPARG TP53 TP63 WRN
3 protein domain specific binding GO:0019904 9.8 HIF1A SIRT1 SNCA TP63
4 transcription regulatory region DNA binding GO:0044212 9.72 JUN PPARG SNCA TP53 TP63
5 identical protein binding GO:0042802 9.7 AKT1 JUN NAMPT PARP1 PPARG SIRT1
6 transcription factor binding GO:0008134 9.63 HIF1A JUN PARP1 PPARG SIRT1 TP53
7 copper ion binding GO:0005507 9.61 SNCA SOD1 TP53
8 p53 binding GO:0002039 9.56 HIF1A SIRT1 TP53 TP63
9 core promoter sequence-specific DNA binding GO:0001046 9.54 PPARG SIRT1 TP53
10 superoxide dismutase activity GO:0004784 9.4 SOD1 SOD2
11 enzyme binding GO:0019899 9.32 AKT1 HIF1A JUN PARP1 PDGFRB PPARG
Sources

Sources for Aging

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....